Ovagen is a biotechnology company and has developed a process for producing germ-free chicken eggs and germ-free birds, in commercial quantities, for use primarily in the pharmaceutical industry. Germ-free eggs are preferential for pharmaceutical use as, currently, eggs produced from normal or specific pathogen-free laying flocks can be infected with bacteria and viruses. Therefore, germ-free eggs provide many advantages over current sources of eggs including a safe, biosecure, large scale, flexible and cost effective biomanufacturing platform for the production of vaccines and therapeutic proteins. Ovagen also provides a Contract Research Service and has extensive expertise in specific pathogen-free poultry, rodent housing and husbandry, in specific poultry and rodent research technologies to GMP standards and in avian transgenics. The company is led and managed by a highly experienced team, including an R&D function which shares combined lifescience experience of over 100 years.